Vascular Dementia (VaD) is a common type of Dementia caused by reduced blood flow to the brain. VaD symptoms may include memory loss, difficulties with thinking, problem-solving, and language. The disorder induces cognitive impairment with strained thinking and judgment in its early stage. Whereas memory is damaged in the later stages.
The available therapies in the Vascular Dementia therapy market comprise drugs that treat the symptoms. However, with notable pharma and biotech companies such as Biogen, Pfizer, Teva Pharmaceuticals, BMS, and several others proactively working in the space, the dynamics of the Vascular Dementia treatment market are anticipated to transform. Discover which pharma player is set to become the trendsetter in the neurological disorders market with its novel therapy through our newsletter.
Learn more about the research & development activities happening in the Vascular Dementia market space, pipeline product assessment. The newsletter offers a complete picture of Vascular Dementia epidemiological insights, current VaD therapy/treatment market scenario, key collaborations, deals and partnerships happening in VaD market domain, investment, and fundings, along with top conferences scheduled to occur in the Vascular Dementia therapy market.
Gain access to the newsletter by filling up the form to the right.
Subscribe to our newsletter series for deep and rich insights into the pharma and healthcare market. Join DelveInsight's emailer list and stay abreast of the latest pharma happenings around the globe.
Stay tuned for more.
Know more about What's covered:
- Indication overview
- Signs, symptoms, and diagnosis
- Epidemiological trends
- Treatment approaches
- R&D in the field
- Top conferences
- News Flash
- Recent Research Activities
- Support from International organizations
- Market insights
- Collaborations and deals in the domain